Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer screening test
Show results for
Products

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Cancer Screening Test Articles & Analysis

14 news found

Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval – IUCPQ-UL) is intended to combine BioMark’s metabolomics liquid biopsy test with radiomics and genetics biomarkers ...

ByBioMark Diagnostics Inc.


Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading central European hospitals*, represented ...

ByBC Platforms


Biomark provides business update and second quarter financial results

Biomark provides business update and second quarter financial results

Poster title: “Quantification of Beta-Hydroxybutyric acid and Tryptophan in plasma as metabolic biomarkers of cancer using the LDTD-MS/MS technique”. The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application. ...

ByBioMark Diagnostics Inc.


ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable ...

ByRarecells Diagnostics SAS


Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022

Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022

The conference will be a remarkable occasion for BioMark to expand its global visibility and cultivate new collaborations with key opinion leaders and institutions as we are planning to introduce our lung cancer screening test early next year.” says Rashid Bux, CEO of BioMark. ...

ByBioMark Diagnostics Inc.


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is ...

ByINOVIQ Ltd


Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

During the second quarter the Company was notified by Novitas, it’s CME intermediary, that pricing for one of its flagship thyroid cancer screening tests was reduced by 70% retroactive to the beginning of 2022. ...

ByInterpace Biosciences


GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

Recommended screening tests only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. More than 70 percent of cancer deaths are from cancers that lack recommended early detection screening. ...

ByGrail, Inc.


New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making

CT About the Oncotype DX and Oncotype MAP™ Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence ...

ByExact Sciences UK, Ltd.


Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...

ByExact Sciences UK, Ltd.


GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test

GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test

With NYSDOH approval, Galleri is now available to residents in the state of New York by prescription to complement existing single cancer screening tests. The standard set by New York State represents one of the most rigorous levels of validation required for laboratory developed tests. ...

ByGrail, Inc.


New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in Node-Positive Early-Stage Breast Cancer

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in Node-Positive Early-Stage Breast Cancer

About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...

ByExact Sciences UK, Ltd.


Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. GRAIL plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients. ...

ByGrail, Inc.


American cancer society choose you day engages employers nationwide in focusing on cancer prevention

American cancer society choose you day engages employers nationwide in focusing on cancer prevention

We are excited that companies and organizations across the country are joining us in celebrating Choose You Day and giving those who drive their companies" success an opportunity to put their health first," said Terry Music, American Cancer Society chief mission delivery officer. Choose You Day celebrates employees putting their health first and helps raise awareness of, and ...

ByCSRwire - Corporate Social Responsibility Newswire

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT